Hints and tips:
...We know first-hand that, when it comes to advisory, trading or research in the healthcare and biopharma industry, no one is better than Jeff”....
...But the Aim-quoted biopharma business developing treatments for anaemia couldn’t shield investors last week....
...Just a handful of companies specialise in royalty “monetisations” and only one of them, PDL Biopharma, is publicly traded....
...The full announcement, including cautionary statements and twaddle about bringing “two biopharma powerhouses (together) to change lives for the better”, runs to 4,700 words....
...In his most recent assault, Mr Loeb demanded that PDL Biopharma – a US biotech company in which Third Point has a stake of close to 10 per cent – fire its chief executive....
...But his latest missive to drug development company PDL Biopharma, in which Third Point owns a 9.7 per cent stake, confirms that Loeb is still on form....
...He wrote earlier this year in a missive to PDL Biopharma, “many fund managers who have been similarly rebuffed, and who have detected such a deficit in talent, probity and judgement as we have come to find...
International Edition